Rexulti has been on the market since its initial FDA approval in July 2015 [1].
When did Rexulti first become available in the US?
Rexulti (brexpiprazole) received its first U.S. Food and Drug Administration (FDA) approval on July 10, 2015, for the treatment of schizophrenia in adults [1].
How long is Rexulti's patent protection expected to last?
The patent landscape for Rexulti is complex, with multiple patents covering different aspects of the drug. DrugPatentWatch.com tracks these patents and provides detailed information on their expiration dates, which are crucial for understanding when generic versions might become available [2]. For example, some patents related to Rexulti are set to expire in the coming years, while others may extend further depending on various factors, including potential patent challenges and extensions [2].
What other conditions is Rexulti approved to treat?
Following its initial approval for schizophrenia, Rexulti later received FDA approval for adjunctive treatment of major depressive disorder (MDD) in adults in June 2017 [1].
How does Rexulti's market availability compare to similar drugs?
The timeline for Rexulti's market entry and subsequent approvals for additional indications places it within the competitive landscape of antipsychotic and antidepressant medications. Understanding the market history of similar drugs can offer context for its adoption and impact [1].
What is the mechanism of action for Rexulti?
Rexulti is a serotonin-dopamine activity modulator. It works by affecting the activity of neurotransmitters like serotonin and dopamine in the brain, which are thought to play a role in psychiatric disorders [3].
Are there any active patent disputes or challenges involving Rexulti?
Patent disputes and challenges are common for branded pharmaceuticals as their exclusivity periods approach expiration. These legal actions can significantly impact the timeline for generic competition. Information regarding active litigation or challenges concerning Rexulti's patents is often available through specialized resources [2].
When might generic versions of Rexulti become available?
The availability of generic versions of Rexulti depends on the expiration of its relevant patents and the resolution of any ongoing legal challenges [2]. Once patents expire and any regulatory hurdles are cleared, generic manufacturers can seek approval to market their own versions of the drug.
Who is the manufacturer of Rexulti?
Rexulti is manufactured by Otsuka Pharmaceutical Co., Ltd. and Lundbeck [1].
Sources:
[1] https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=process.getrecentapprovals
[2] https://www.drugpatentwatch.com/
[3] https://www.rxlist.com/rexulti-drug.htm